Tirzepatide

Description

Tirzepatide (marketed under brand names Mounjaro and Zepbound) is a dual incretin receptor agonist that targets both the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. By activating these two pathways simultaneously, Tirzepatide enhances insulin secretion, improves glycemic control, and significantly reduces appetite.

This dual mechanism makes it more effective for body fat reduction and metabolic improvements compared to earlier GLP-1–only therapies such as Semaglutide. In clinical studies, Tirzepatide has shown marked benefits for weight loss, blood sugar regulation, and overall metabolic health, positioning it as one of the most advanced treatments available for type 2 diabetes and obesity management.